A pre-existing coordinated inflammatory microenvironment is associated with complete response of vulvar high-grade squamous intraepithelial lesions to different forms of immunotherapy.

Abstract

Immunotherapy of vulvar high-grade squamous intraepithelial lesion (vHSIL) is investigated as an alternative for surgery, because of high comorbidity and risk of recurrence. Limited evidence exists on the role and composition of the immune microenvironment in current immunotherapeutic approaches for vHSIL. The vHSIL of 29 patients biopsied before treatment with imiquimod were analyzed by two multiplex seven-color immunofluorescence panels to investigate the pre-existing T-cell and myeloid cell composition in relation to treatment response. The samples were scanned with the Vectra multispectral imaging system. Cells were automatically phenotyped and counted with inForm advanced image analysis software. Cell counts and composition were compared to that of vHSIL patients before therapeutic vaccination (n = 29) and to healthy vulva (n = 27). Our data show that the immune microenvironment of complete responders (CR) to imiquimod resembled the coordinated infiltration with type 1 CD4+ and CD8+ T cells and CD14+ inflammatory myeloid cells also found in healthy vulva. However, more CD8+ T cells and FoxP3+ regulatory T cells were present in CR. The lesions of partial responders (PR) lacked such a coordinated response and displayed an impaired influx of CD14+ inflammatory myeloid cells. Importantly, complete responses after imiquimod or therapeutic vaccination showed the same dependency on a pre-existing coordinated type 1 T-cell and CD14+ myeloid cell infiltration. In conclusion, a good clinical outcome after two different forms of immunotherapy for vHSIL is associated with the presence of a primary inflammatory process resulting in the coordinated influx of several types of immune cells which is then amplified.

• Authors: Ziena Abdulrahman, Noel F C C de Miranda, Bart W J Hellebrekers, Peggy J de Vos van Steenwijk, Edith M G van Esch, Sjoerd H van der Burg, Mariette I E van Poelgeest
• Journal: International journal of cancer (Int J Cancer) Vol. 147 Issue 10 Pg. 2914-2923 (11 15 2020) ISSN: 1097-0215 [Electronic] United States
• PMID: 32574376 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2020 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

Chemical References

• Adjuvants, Immunologic
• Imiquimod

Topics

• Adjuvants, Immunologic (administration & dosage, pharmacology)
• Adult
• Aged
• CD4-Positive T-Lymphocytes (drug effects, metabolism)
• CD8-Positive T-Lymphocytes (drug effects, metabolism)
• Case-Control Studies
• Cell Count
• Female
• Humans
• Imiquimod (administration & dosage, pharmacology)
• Immunotherapy
• Middle Aged
• Myeloid Cells (drug effects, metabolism)
• Neoplasm Grading
• Squamous Intraepithelial Lesions (drug therapy, immunology, pathology)
• Treatment Outcome
• Tumor Microenvironment (drug effects)
• Vulvar Neoplasms (drug therapy, immunology, pathology)